Explore why high‑risk CLL often favors continuous BTK inhibitors over time‑limited venetoclax, balancing efficacy with clinic-visit burden.
Deborah Stephens, DO
Deborah Stephens, DO, is Associate Professor of Medicine, Director of the Chronic Lymphocytic Leukemia and Richter's Program, and Physician Leader of CLL and Lymphoma Research Program at UNC School of Medicine.
Articles by Deborah Stephens, DO
Long-term zanubrutinib keeps atrial fibrillation risk low while manageable hypertension, neutropenia and infections emerge with continued therapy.